MarketWatchT3·36mo ago
BMED iShares Health Innovation Active ETF
ETF 37.23 DelayedETF quote, holdings, sector allocation, technicals, and options analytics. Expected move IV rank history Fibonacci levels
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
BMED
$37.23
—
Key stats
$37.23
- 52-Week Range
- $27.25 – $37.30
- YTD
- +22.69%
- IV Rank (30D)
- 24.8
- Straddle Price
- $2.05
- Open
- $36.89
- Day Range
- $36.69 – $37.30
- Volume
- 38,255
- Prev Close
- $36.28
About
iShares Health Innovation Active ETF (BMED) ETF
No description available.
- Exchange
- ARCX
- Inception
- 2020-09-29
- Has Options
- Yes
- Homepage
- https://www.ishares.com/us
Fund profile
holdings as of Nov 2, 2026issuer datathrough Jul 2026flows, SEC filings
- Expense ratio
- 0.55% issuer, Nov 4, 2026
- Assets
- $14M issuer-reported, Nov 2, 2026
- Trailing yield
- 0.22% paid semi-annual
- Average daily volume
- $77K 30 sessions
- Holdings
- 62 top 10 are 42.7%
- Listed
- Sep 29, 2020 NYSE Arca
- Last fee change
- -30 bp filed Nov 21, 2025
- Net asset value
- $36.24 issuer, Nov 3, 2026 · closed +0.12% to NAV
- Median bid/ask spread
- 0.23% 30 days, issuer-reported
- 30-day SEC yield
- 0.36% issuer, Sep 30, 2026
- Return on NAV, 1 year
- +29.0% issuer, through Sep 30, 2026 · 3 years +15.5% a year · 5 years +3.4%
- Distributions, 12 months
- $0.08 a share issuer, through Jun 15, 2026: 100% income
Cost49
Liquidity0
Scale6
Diversification62
Moves with. US large-cap stocks (18% of its variance, beta 0.61); Long Treasuries (8% of its variance, beta 0.40); Small caps over large (6% of its variance, beta 0.28); Developed markets ex-US over US (4% of its variance, beta 0.24). These factors explain 38% of its daily moves over the last year.
Stated objective. The iShares Health Innovation Active ETF (the Fund) seeks to maximize total return. (from the fund's prospectus)
All 62 holdingsFlow historySimilar fundsOverlap toolAll Internet & Innovation ETFs
Fund flows
daily as of Nov 2, 2026issuer datathrough Jul 2026SEC filings- Nov 2, 2026
- $0 latest day
- Latest 5 trading days
- $0
- Latest 21 trading days
- $0 0.0% of assets
- Year to date
- +$5.0M +$6.3M over 12 months
Each day
| Day | Net flow |
|---|---|
| Nov 2, 2026 | $0 |
| Oct 30, 2026 | $0 |
| Oct 29, 2026 | $0 |
| Oct 28, 2026 | $0 |
| Oct 27, 2026 | $0 |
| Oct 26, 2026 | $0 |
| Oct 23, 2026 | $0 |
| Oct 22, 2026 | $0 |
| Oct 21, 2026 | $0 |
| Oct 20, 2026 | $0 |
| Oct 19, 2026 | $0 |
| Oct 16, 2026 | $0 |
| Oct 15, 2026 | $0 |
| Oct 14, 2026 | $0 |
| Oct 13, 2026 | $0 |
| Oct 12, 2026 | $0 |
| Oct 9, 2026 | $0 |
| Oct 8, 2026 | $0 |
| Oct 7, 2026 | $0 |
| Oct 6, 2026 | $0 |
| Oct 5, 2026 | $0 |
Daily figures are the change in shares outstanding times net asset value, both as the issuer publishes them each day.
- Jul 2026
- $0 latest reported month
- Latest 3 months
- $0 0.0% of assets
- Latest 12 months
- +$6.1M +54.7% of assets
View as a table
| Month | Net flow |
|---|---|
| Jul 2026 | $0 |
| Jun 2026 | $0 |
| May 2026 | $0 |
| Apr 2026 | $0 |
| Mar 2026 | $0 |
| Feb 2026 | +$1.2M |
| Jan 2026 | +$2.5M |
| Dec 2025 | +$1.2M |
| Nov 2025 | $0 |
| Oct 2025 | +$1.1M |
| Sep 2025 | $0 |
| Aug 2025 | $0 |
Net creations and redemptions from the fund's SEC filings, which become public about 60 days after each quarter. Every month since 70 months ago
Similar funds
| Fund | Overlap | Fee | Assets | 1Y | |
|---|---|---|---|---|---|
| JDOCJPMorgan Healthcare Leaders ETF | 37% | 0.65% | $9.8M | +19.2% | compare |
| IXJiShares Global Healthcare ETF | 36% | 0.38% | $4.6B | +22.8% | compare |
| RSPHInvesco S&P 500 Equal Weight Health Care ETF | 36% | 0.40% | $985M | +32.2% | compare |
| FTXHFirst Trust Nasdaq Pharmaceuticals ETF | 35% | 0.60% | $1.2B | +45.4% | compare |
| GDOCGoldman Sachs Future Health Care Equity ETF | 35% | 0.75% | $20M | +12.0% | compare |
Ranked by how much of the two portfolios is the same securities.
Look-through: what the holdings say
weights as of Nov 2, 2026issuer data- Holdings vs fair value
- +0.9% 21% under, 34% over · 91% covered
- Price / earnings
- 104.6 27% loss-making · 86% covered
- Price / book · sales
- 5.6 · 4.4 revenue growth +6.7%
- Above 200-day average
- 95% 76% above 50-day · by weight
- Short interest
- 4.4% of float, weighted · 3.6 days to cover
- Insider buying
- 2% of weight had net insider buying, 90 days; 46% net selling
- 13F holders
- +3.5% change in shares held by institutions, latest quarter
- Reporting earnings
- 28.8% of weight in 7 days; 29.0% in 14
Holdings reporting in the next 14 days · weighted implied move this week 3.23%
Each figure is the fund's holdings weighted by position size, using our data on those stocks, and covers only the share of the stock holdings stated. Positive fair value means the holdings trade below our estimate.
What changed in the portfolio
Oct 26, 2026 → Oct 27, 2026| Action | Holding | Weight before | Weight after | Shares vs flows |
|---|---|---|---|---|
| Increase | DNTHDIANTHUS THERAPEUTICS | 0.41% | 0.50% | +23.1% |
0 new, 0 exited, 0 increased and 0 decreased between the fund's two latest holdings reports; turnover 0.7%. Full holdings and history
Under the hood
fiscal year to Jul 31, 2025SEC census- Authorized participants
- 2 active of 36 with agreements; top 3 did 100%
- Created · redeemed
- $985K · $1.0M over the fiscal year
- Redemptions in kind
- 94% creations 93% in kind
- Creation unit
- 40,000 shares
- Securities lending
- 6.00% of assets on loan on average; earned 3.0 bp
From the fund's annual census filing with the SEC. In-kind redemptions are what let an ETF shed appreciated securities without realising gains.
ETF Profile
holdings as of 2026-11-02
Holdings
62
AUM
$14.5M
Provider
iShares (BlackRock)
Inception
2020-09-29
Exchange
ARCX
Data As Of
2026-11-02
Expense Ratio
0.55%
Dividend Yield
0.22%
Distribution
Semi-Annual
Recent distributions
| Ex-Date | Pay Date | Amount | Type |
|---|---|---|---|
| 2026-06-15 | 2026-06-18 | $0.0812 | CD |
| 2023-12-20 | 2023-12-27 | $0.0072 | CD |
Asset Allocation
Top Holdings
top 50 of 62 holdings
| Symbol | Name | Weight % | Asset Class | Country |
|---|---|---|---|---|
| GILD | GILEAD SCIENCES | 5.95% | Equity (US) | US |
| — | BLK CSH FND TREASURY SL AGENCY | 5.34% | Cash/Money Market | US |
| MRNA | MODERNA | 5.32% | Equity (US) | US |
| DHR | DANAHER | 5.11% | Equity (US) | US |
| ABBV | ABBVIE | 4.87% | Equity (US) | US |
| TMO | THERMO FISHER SCIENTIFIC | 4.27% | Equity (US) | US |
| BIIB | BIOGEN | 3.71% | Equity (US) | US |
| MTD | METTLER TOLEDO | 3.54% | Equity (US) | US |
| IQV | IQVIA HOLDINGS INC | 3.45% | Equity (US) | US |
| VRTX | VERTEX PHARMACEUTICALS | 3.39% | Equity (US) | US |
| EW | EDWARDS LIFESCIENCES | 3.06% | Equity (US) | US |
| MRK | MERCK & CO INC | 3.03% | Equity (US) | US |
| ROP | ROCHE PS PAR AG | 2.87% | Equity (Foreign) | CH |
| GMAB | GENMAB SPONSORED ADR | 2.75% | Equity (Foreign) | DK |
| AMGN | AMGEN INC | 2.59% | Equity (US) | US |
| A | AGILENT TECHNOLOGIES INC | 2.35% | Equity (US) | US |
| DXCM | DEXCOM INC | 2.28% | Equity (US) | US |
| HALO | HALOZYME THERAPEUTICS | 2.26% | Equity (US) | US |
| WAT | WATERS CORP | 2.21% | Equity (US) | US |
| ARGX | ARGENX SE ADR | 1.68% | Equity (Foreign) | BE |
| CRL | CHARLES RIVER LABORATORIES INTERNA | 1.62% | Equity (US) | US |
| PFE | PFIZER | 1.57% | Equity (US) | US |
| ILMN | ILLUMINA INC | 1.56% | Equity (US) | US |
| GALD | GALDERMA GROUP N AG | 1.45% | Equity (Foreign) | CH |
| NBIX | NEUROCRINE BIOSCIENCES | 1.39% | Equity (US) | US |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES | 1.39% | Equity (Foreign) | IL |
| GH | GUARDANT HEALTH | 1.38% | Equity (US) | US |
| BMY | BRISTOL MYERS SQUIBB | 1.34% | Equity (US) | US |
| ABT | ABBOTT LABORATORIES | 1.33% | Equity (US) | US |
| NOVN | NOVARTIS AG | 1.30% | Equity (Foreign) | CH |
| ROIV | ROIVANT SCIENCES LTD | 1.29% | Equity (US) | US |
| MRK | MERCK | 1.25% | Equity (Foreign) | DE |
| CYTK | CYTOKINETICS | 1.24% | Equity (US) | US |
| JNJ | JOHNSON & JOHNSON | 1.22% | Equity (US) | US |
| — | WUXI BIOLOGICS CAYMAN | 1.14% | Equity (Foreign) | CN |
| BMRN | BIOMARIN PHARMACEUTICAL | 1.01% | Equity (US) | US |
| COR | CENCORA | 0.98% | Equity (US) | US |
| TEM | TEMPUS AI CLASS A | 0.95% | Equity (US) | US |
| PTGX | PROTAGONIST THERAPEUTICS | 0.84% | Equity (US) | US |
| UCB | UCB SA | 0.80% | Equity (Foreign) | BE |
| AXSM | AXSOME THERAPEUTICS | 0.68% | Equity (US) | US |
| BRKR | BRUKER | 0.64% | Equity (US) | US |
| ALKS | ALKERMES | 0.59% | Equity (US) | US |
| RVMD | REVOLUTION MEDICINES | 0.54% | Equity (US) | US |
| DNTH | DIANTHUS THERAPEUTICS | 0.51% | Equity (US) | US |
| PTCT | PTC THERAPEUTICS | 0.42% | Equity (US) | US |
| MBX | MBX BIOSCIENCES | 0.42% | Equity (US) | US |
| COGT | COGENT BIOSCIENCES | 0.37% | Equity (US) | US |
| VRDN | VIRIDIAN THERAPEUTICS ORS | 0.36% | Equity (US) | US |
| SGMT | SAGIMET BIOSCIENCES SERIES A | 0.13% | Equity (US) | US |
Geographic Breakdown
Non-Equity Breakdown
iShares Health Innovation Active ETF ·
NPORT-P period 2026-07-31
(filed 2026-09-25)
Net assets:
$11M
· 58 total positions
· equity 95.63%
· non-equity 5.49%
Non-equity holdings
— 7 positions,
5.49% of NAV
| Category | Weight | Value | Positions |
|---|---|---|---|
| Short-term investment | 5.48% | $611332 | 2 |
| Other | 0.01% | $771 | 5 |
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 0.34% | -12.92% | 3.82% | 1.04% | 6.38% | 2.41% | 0.18% |
| Feb | -2.36% | -1.79% | -5.33% | 2.83% | -2.91% | -0.92% | -1.75% |
| Mar | -6.62% | 1.98% | 2.05% | 0.26% | -4.65% | -5.83% | -2.14% |
| Apr | 4.53% | -10.66% | 3.60% | -6.51% | 2.27% | -3.37% | -1.69% |
| May | -1.81% | -2.23% | -3.63% | 0.35% | -0.13% | 3.15% | -0.72% |
| Jun | 4.03% | -0.60% | 4.13% | 0.38% | 2.46% | 7.84% | 3.04% |
| Jul | -1.74% | 2.80% | 0.62% | 4.42% | -0.56% | -1.74% | 0.63% |
| Aug | 1.30% | -3.70% | -2.47% | 1.09% | 5.46% | 9.49% | 1.86% |
| Sep | -4.40% | -6.13% | -6.91% | 0.39% | 1.91% | 1.93% | -2.20% |
| Oct | 0.91% | 4.86% | -6.43% | -2.04% | 3.83% | 8.08% | 1.54% |
| Nov | -8.18% | 4.80% | 6.79% | 1.62% | 9.42% | 3.32%* | 2.96% |
| Dec | 6.20% | -2.52% | 8.36% | -4.98% | -0.35% | -- | 1.34% |
| Total | -8.53% | -24.62% | 3.14% | -1.67% | 24.70% | 25.77% | 3.13% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $35.32
SMA 50: $34.54
SMA 200: $31.02
Current: $37.30
EMA 12: $36.01
EMA 26: $35.32
MACD: 0.6883 | Signal: 0.1404
BULLISH
ADX (14): 26.73
TREND
+DI: 48.44
−DI: 18.31
Momentum Oscillators
RSI (14): 69.53
NEUTRAL
Stoch %K: 79.72
Stoch %D: 79.39
Williams %R: 0.00
Volume & Volatility
BB Upper: $37.25
BB Lower: $33.40
OVERBOUGHT
OBV: 144,796
Vol SMA 20: 3,851
Vol ROC: 3429.06%
ATR: $0.50
True Range: $1.02
HV 20: 20.3%
HV 30: 20.9%
HV 60: 22.6%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-04T00:00:00 – 2026-11-04T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL (confidence level: 6/10)
Key drivers:
- Technical momentum signals point to a short-term bullish trend, with the MACD indicating a strong upward momentum
- News sentiment has been neutral recently, without any significant market-moving events
- Beta analysis suggests low volatility, which could indicate lower risk for this stock
Primary risks:
- Overbought RSI levels may lead to a pullback or consolidation
- Low volume and open interest in options markets suggest limited institutional activity
Investment thesis: BMED is likely to experience short-term momentum-driven gains, but may face resistance at the upper Bollinger Band. A potential correction could set up a more favorable entry point for investors.
Recent news sentiment impact: The recent neutral market pulse headlines have not significantly impacted the stock's price movement, suggesting that the current trend is driven by technical factors rather than news events.
Technical Analysis
Trend Direction: Short-term bullish (1-4 weeks), Medium-term neutral (1-3 months), Long-term bearish (3-12 months)
Support/Resistance Levels: $30.75 (SMA 50) and $29.87 (SMA 200) are key levels to monitor for potential support; the upper Bollinger Band ($34.13) is a resistance level.
Momentum Signals:
- RSI: Overbought (78.47), indicating potential sell signal
- MACD: Bullish crossover above signal line, confirming upward momentum
- Bollinger Bands: Price touching upper band, suggesting overbought conditions
Volume Analysis: Volume trends suggest low institutional activity, with no significant changes in recent days.
News & Sentiment Analysis
Recent Headlines Summary: The two recent headlines are neutral market commentary, without any significant market-moving events.
Sentiment Assessment: Neutral sentiment is reflected in the recent news headlines and lack of significant price movement.
Catalyst Identification: No upcoming earnings or regulatory changes are identified as potential catalysts for this stock.
Risk & Volatility Assessment
Beta Interpretation: Beta (0.55) suggests low volatility, indicating lower risk for this stock compared to the broader market.
Volatility Regime: Historical volatility is relatively low, which could indicate a more stable price environment.
Options Market Signals: IV rank is 24.0% (low), suggesting historically low volatility; options activity is limited, with no significant unusual events or order flow observed.
Market Context & Positioning
Sector Performance: BMED's sector is performing similarly to the broader market, without any significant outperformance or underperformance.
Institutional Activity: Low volume and open interest in options markets suggest limited institutional activity, which could indicate a lack of investor conviction.
Correlation Analysis: The stock's price movement is relatively independent from the broader market, with an R-squared value indicating low correlation.
Key Levels & Action Items
Critical Price Levels: $30.75 (SMA 50) and $29.87 (SMA 200) are key levels to monitor for potential support; the upper Bollinger Band ($34.13) is a resistance level.
Breakout/Breakdown Levels: A break above the upper Bollinger Band could trigger further upward momentum, while a breakdown below SMA 50 could indicate a trend reversal.
Time-Sensitive Catalysts: No upcoming earnings or regulatory changes are identified as potential catalysts for this stock.
Risk Management: Consider setting stop-loss levels at $30.75 (SMA 50) and $29.87 (SMA 200) to manage risk; position sizing should be adjusted based on individual risk tolerance.
Generated
News
All BMED news →
Seeking AlphaT3·61mo ago
BMED Options Activity & IV Rank
BMED IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 23.4%
7-DTE IV: 26.8%
Expected Move: $2.05
7-DTE Move: $2.05
Days to Exp: 16 (2026-11-20)
Options Flow
Call Volume: 0
Put Volume: 0
P/C Volume: —
Call OI: 0
Put OI: 0
P/C OI: —
Total OI: 0
ATM Options Pricing
ATM Call: $1.00
ATM Put: $1.05
Call %: 2.7%
Put %: 2.8%
Chain Summary
Chain Volume: 0
Chain OI: 0
Last Updated: 11/4/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Nov 4 · ATM 30.2% / Wing —
30 DTE / 10d
—
—
pts
EXTREME
as of Nov 4 · No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)4.9LowNov 4
IV Rank (30 DTE)24.8LowNov 4
Straddle Price (30 DTE)$2.05Nov 4
Beta Analysis
Risk Metrics
Beta: 0.6025
Alpha: 21.72%
Correlation: 0.4269
R-Squared: 18.2%
Stock Volatility: 18.2%
Market Volatility: 12.9%
Analysis Details
Benchmark: SPY
Data Points: 249
Period: 252 trading days
Data Points: 249
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
BMED Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
4.59K
SI % of Float
1.15%
Days to Cover
2.27
Short Vol Ratio
18.1%
Free Float
—
Float %
—
Short interest 2026-10-15 • Short volume 2026-11-04
BMED Constituent Performance
Click any bar to view the full quote for that stock.
BMED Constituents (50 of 54)
| Symbol | Name | Weight % | Price | 1 Day | 1 Week | 1 Month |
|---|---|---|---|---|---|---|
| GILD | GILEAD SCIENCES | 5.95% | $174.48 | +4.19% | +9.60% | +18.82% |
| MRNA | MODERNA | 5.32% | $258.38 | +13.11% | +20.65% | +31.50% |
| DHR | DANAHER | 5.11% | $234.93 | +2.09% | +0.37% | +7.52% |
| ABBV | ABBVIE | 4.87% | $294.83 | +3.09% | +3.09% | +8.65% |
| TMO | THERMO FISHER SCIENTIFIC | 4.27% | $706.16 | +1.12% | +0.29% | +6.66% |
| BIIB | BIOGEN | 3.71% | $254.46 | +2.22% | +4.27% | +14.54% |
| MTD | METTLER TOLEDO | 3.54% | $1723.24 | +1.48% | +1.46% | +12.37% |
| IQV | IQVIA HOLDINGS INC | 3.45% | $263.79 | +0.46% | -5.47% | +2.20% |
| VRTX | VERTEX PHARMACEUTICALS | 3.39% | $549.04 | +3.44% | +3.65% | +8.58% |
| EW | EDWARDS LIFESCIENCES | 3.06% | $99.37 | +4.39% | +8.27% | +15.84% |
| ROP | ROCHE PS PAR AG | 2.87% | $492.22 | +3.94% | +11.70% | +37.27% |
| GMAB | GENMAB SPONSORED ADR | 2.75% | $55.12 | -0.72% | -3.79% | +50.40% |
| AMGN | AMGEN INC | 2.59% | $478.48 | +3.73% | +5.90% | +15.83% |
| A | AGILENT TECHNOLOGIES INC | 2.35% | $177.17 | +0.97% | -2.37% | +4.78% |
| DXCM | DEXCOM INC | 2.28% | $88.48 | +6.64% | +12.54% | +4.96% |
| HALO | HALOZYME THERAPEUTICS | 2.26% | $130.34 | +1.34% | +0.24% | +17.65% |
| WAT | WATERS CORP | 2.21% | $467.6 | +1.67% | -1.95% | +7.25% |
| ARGX | ARGENX SE ADR | 1.68% | $931.38 | +3.36% | +4.44% | +0.32% |
| CRL | CHARLES RIVER LABORATORIES INTERNA | 1.62% | $326.29 | -7.27% | -12.75% | +8.65% |
| PFE | PFIZER | 1.57% | $30.79 | +2.63% | +4.55% | +9.96% |
| ILMN | ILLUMINA INC | 1.56% | $226.54 | -4.90% | -21.56% | -15.39% |
| NBIX | NEUROCRINE BIOSCIENCES | 1.39% | $166.05 | +0.73% | +14.10% | +15.74% |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES | 1.39% | $41.85 | -0.14% | +4.70% | +6.81% |
| GH | GUARDANT HEALTH | 1.38% | $168.58 | -3.67% | -7.67% | +0.15% |
| BMY | BRISTOL MYERS SQUIBB | 1.34% | $64.19 | +4.02% | +5.98% | +7.52% |
| ABT | ABBOTT LABORATORIES | 1.33% | $115.51 | +5.59% | +12.54% | +17.00% |
| NOVN | NOVARTIS AG | 1.30% | $0.09 | -24.84% | -44.12% | -77.43% |
| ROIV | ROIVANT SCIENCES LTD | 1.29% | $38.23 | +6.08% | +3.02% | +10.01% |
| MRK | MERCK | 1.25% | $150.36 | +3.93% | +6.69% | +5.30% |
| CYTK | CYTOKINETICS | 1.24% | $63.6 | +2.07% | +3.79% | +4.06% |
| JNJ | JOHNSON & JOHNSON | 1.22% | $276.32 | +3.81% | +1.95% | +6.91% |
| BMRN | BIOMARIN PHARMACEUTICAL | 1.01% | $57.13 | +2.64% | +2.02% | +3.50% |
| COR | CENCORA | 0.98% | $354 | +3.96% | +9.14% | +11.58% |
| TEM | TEMPUS AI CLASS A | 0.95% | $75.61 | -2.81% | -1.31% | +7.48% |
| PTGX | PROTAGONIST THERAPEUTICS | 0.84% | $143.37 | +2.23% | +0.87% | +1.74% |
| UCB | UCB SA | 0.80% | $37.66 | +1.67% | +3.01% | +13.23% |
| AXSM | AXSOME THERAPEUTICS | 0.68% | $137 | -1.87% | -4.54% | -20.80% |
| BRKR | BRUKER | 0.64% | $63.79 | +12.90% | +2.89% | +6.82% |
| ALKS | ALKERMES | 0.59% | $45.89 | +0.44% | +1.41% | +10.73% |
| RVMD | REVOLUTION MEDICINES | 0.54% | $199.7 | +2.82% | +5.82% | -0.58% |
| DNTH | DIANTHUS THERAPEUTICS | 0.51% | $85.81 | +3.76% | +4.25% | +1.10% |
| PTCT | PTC THERAPEUTICS | 0.42% | $68.97 | +1.25% | +9.44% | +9.08% |
| MBX | MBX BIOSCIENCES | 0.42% | $52.48 | -4.58% | -3.10% | -3.78% |
| COGT | COGENT BIOSCIENCES | 0.37% | $31.49 | +1.38% | -2.30% | +4.48% |
| VRDN | VIRIDIAN THERAPEUTICS ORS | 0.36% | $29.05 | +15.53% | +19.72% | +58.94% |
| SGMT | SAGIMET BIOSCIENCES SERIES A | 0.13% | $9.99 | +0.40% | -6.98% | +12.50% |
| SMMT | SUMMIT THERAPEUTICS | 0.07% | $16.17 | +2.34% | +2.54% | -9.92% |
| EIKN | EIKON THERAPEUTICS | 0.05% | $6.39 | +15.14% | +15.34% | -15.25% |
| AVTX | AVALO THERAPEUTICS | 0.04% | $7.07 | -2.48% | -0.70% | -47.94% |
| MRTX | MIRATI THERAPEUTICS INC | 0.00% | $58.7 | -0.17% | -0.98% | -0.44% |